| | |  | | | | Record from Web of Science® | | | | | | |
| TREATMENT OF ESTABLISHED RENAL-CANCER BY TUMOR-CELLS ENGINEERED TO SECRETE INTERLEUKIN-4 |
|
|
| Author(s): GOLUMBEK PT, LAZENBY AJ, LEVITSKY HI, JAFFEE LM, KARASUYAMA H, BAKER M, PARDOLL DM |
| Source: SCIENCE Volume: 254 Issue: 5032 Pages: 713-716 Published: NOV 1 1991 |
| Times Cited: 718 References: 29 |
| Abstract: The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses of interleukin-4 (IL-4) locally, they were rejected in a predominantly T cell-independent manner. However, animals that rejected the IL-4-transfected tumors developed T cell-dependent systemic immunity to the parental tumor. This systemic immunity was tumor-specific and primarily mediated by CD8+ T cells. Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors. These results provide a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy. |
| Document Type: Article |
| Language: English |
Addresses:
1. JOHNS HOPKINS UNIV, DEPT MED, BALTIMORE, MD 21205 USA
2. JOHNS HOPKINS UNIV, DEPT PATHOL, BALTIMORE, MD 21205 USA
3. JOHNS HOPKINS UNIV, DEPT IMMUNOL, BALTIMORE, MD 21205 USA |
| Publisher: AMER ASSOC ADVANCEMENT SCIENCE, 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 |
| Subject Category: Multidisciplinary Sciences |
| IDS Number: GN474 |
| ISSN: 0036-8075 |
|
| | | | | | | | | Record from Web of Science® | | | | | | | | | |